Search hospitals > Nevada > Las Vegas
Comprehensive Cancer Centers of Nevada-Summerlin
Claim this profileLas Vegas, Nevada 89144
Global Leader in Skin Cancer
Global Leader in Lung Cancer
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Stomach Cancer
192 reported clinical trials
3 medical researchers
Summary
Comprehensive Cancer Centers of Nevada-Summerlin is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Skin Cancer, Lung Cancer, Cancer, Breast Cancer, Stomach Cancer and other specialties. Comprehensive Cancer Centers of Nevada-Summerlin is involved with conducting 192 clinical trials across 346 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Henry Igid, MD.Area of expertise
1Skin Cancer
Global LeaderStage IV
Stage III
Stage I
2Lung Cancer
Global LeaderStage IV
Stage II
Stage I
Top PIs
John A. EllertonOptumCare Cancer Care at Fort Apache6 years of reported clinical research
Expert in Skin Cancer
Expert in Breast Cancer
158 reported clinical trials
235 drugs studied
Alan K. IkedaAlliance for Childhood Diseases/Cure 4 the Kids Foundation7 years of reported clinical research
Expert in Uterine Tumors
Expert in T-Lymphoblastic Leukemia/Lymphoma
55 reported clinical trials
111 drugs studied
Henry Igid, MDComprehensive Cancer Centers of Nevada - Town Center4 years of reported clinical research
Studies B-Cell Lymphoma
Studies Diffuse Large B-Cell Lymphoma
1 reported clinical trial
7 drugs studied
Clinical Trials running at Comprehensive Cancer Centers of Nevada-Summerlin
Breast Cancer
Bladder Cancer
Lung Cancer
Skin Cancer
Prostate Cancer
Bladder Carcinoma
Stomach Cancer
Kidney Cancer
Uterine Tumors
Testicular cancer
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Mobile Health
for Breast Cancer
This clinical trial compares the use of the connected customized treatment platform (CONCURxP), consisting of using a medication monitoring device called WiseBag along with text message reminders for missed or extra medication events, to enhanced usual care (EUC), where patients only use the WiseBag, to monitor medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor. To ensure CDK4/6 inhibitors achieve their full clinical benefit, patients need to take them as prescribed, following a complex treatment schedule. Forgetfulness was the most common reason reported for medication non adherence. Using the WiseBag along with CONCURxP or enhanced usual care may improve medication adherence in patients with metastatic breast cancer who are taking a CKD4/6 inhibitor.
Recruiting1 award N/A10 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Comprehensive Cancer Centers of Nevada-Summerlin?
Comprehensive Cancer Centers of Nevada-Summerlin is a medical facility located in Las Vegas, Nevada. This center is recognized for care of Skin Cancer, Lung Cancer, Cancer, Breast Cancer, Stomach Cancer and other specialties. Comprehensive Cancer Centers of Nevada-Summerlin is involved with conducting 192 clinical trials across 346 conditions. There are 3 research doctors associated with this hospital, such as John A. Ellerton, Alan K. Ikeda, and Henry Igid, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.